{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.626","value":"7.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"title":"Baseline HbA1c"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.014","value":"-0.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"title":"Change from Baseline in HbA1c at Week 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"}],"paramType":"MEAN","populationDescription":"The analysis population was patients in the mITT-OL Population who had DM/IGT at Baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 22 (end of OL Phase)","title":"Change in Hemoglobin HbA1c During the OL Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage"}